ESTIMATING UTILITY VALUES USING THE DUCHENNE MUSCULAR DYSTROPHY-QUALITY OF LIFE MEASURE (DMD-QOL): A NEW PREFERENCE-BASED MEASURE FOR DUCHENNE MUSCULAR DYSTROPHY

被引：0
|
作者：
Bever, A. [1 ]
Audhya, I. Filipovic [2 ]
Szabo, S. [1 ]
Jayasinghe, P. [1 ]
Feeny, D. [3 ]
Neumann, P. [4 ]
Malone, D. C. [5 ]
Iannaccone, S. T. [6 ]
Gooch, K. L. [2 ]
机构：
[1] Broadst Hlth Econ & Outcomes Res, Vancouver, BC, Canada
[2] Sarepta Therapeut, Cambridge, MA USA
[3] McMaster Univ, Hamilton, ON, Canada
[4] Tufts Med Ctr, Boston, MA USA
[5] Univ Utah, Salt Lake City, UT USA
[6] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCR230
引用
收藏
页码：S355 / S355
页数：1
相关论文
共 50 条
  • [21] Quality of life of adult patients with Duchenne muscular dystrophy
    Kobayashi, M.
    Obara, K.
    Abe, E.
    Wada, C.
    Toyoshima, I.
    NEUROMUSCULAR DISORDERS, 2013, 23 (9-10) : 774 - 774
  • [22] Evaluation of the quality of life in patients with Duchenne Muscular Dystrophy
    Simon, V. A.
    Simon, M. A. V.
    Godoy, A. J.
    Resende, M. B. D.
    Zanoteli, E.
    Reed, U. C.
    NEUROMUSCULAR DISORDERS, 2011, 21 (9-10) : 652 - 652
  • [23] Stride to height ratio as a new ambulatory outcome measure in Duchenne muscular dystrophy
    Henricson, E.
    Abresch, R.
    Bagley, A.
    Goude, E.
    Owens, C.
    Williams, L.
    McDonald, C.
    NEUROMUSCULAR DISORDERS, 2018, 28 : S125 - S126
  • [24] Factors Associated To Quality Of Life (qol) In Patients Affected By Amyotrophic Lateral Sclerosis (als) And Duchenne Muscular Dystrophy (dmd)
    Crescimanno, G.
    Greco, F.
    Spatola, M.
    Marrone, O.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [25] Breathing new life into therapies for Duchenne muscular dystrophy
    O'Halloran, Ken D.
    JOURNAL OF PHYSIOLOGY-LONDON, 2022, 600 (15): : 3453 - 3454
  • [26] Clinical approaches in the treatment of Duchenne muscular dystrophy (DMD) using oligonucleotides
    Bertoni, Carmen
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2008, 13 : 517 - 527
  • [27] Dystrophin as a biochemical outcome measure in Duchenne muscular dystrophy clinical trials
    Sardone, V.
    Ellis, M.
    Torelli, S.
    Feng, L.
    Chambers, D.
    Ricotti, V.
    Domingos, J. Pisco
    Phadke, R.
    Sewry, C. A.
    Morgan, J.
    Muntoni, F.
    NEUROMUSCULAR DISORDERS, 2016, 26 : S16 - S16
  • [28] TIME TRADE-OFF UTILITY VALUES FOR HEALTH STATES CHARACTERIZING PROGRESSIVE MUSCULAR DEGENERATION IN DUCHENNE MUSCULAR DYSTROPHY (DMD)
    Audhya, Filipovic, I
    Szabo, S.
    Bever, A. E.
    Malone, D. C.
    Feeny, D.
    Neumann, P., I
    Bolatova, T.
    Iannaccone, S. T.
    Gooch, K. L.
    VALUE IN HEALTH, 2022, 25 (07) : S574 - S574
  • [29] Fractures, Functional Status, and Health-related Quality of Life in Duchenne Muscular Dystrophy (DMD)
    Riss, V. J.
    Finanger, E. L.
    Russman, B. S.
    ANNALS OF NEUROLOGY, 2012, 72 : S230 - S230
  • [30] Correlation of Quality of Life with Disease Course and Severity in an Irish Duchenne Muscular Dystrophy(DMD) Population
    McSweeney, N.
    Lynch, B.
    ANNALS OF NEUROLOGY, 2010, 68 (04) : S96 - S96
12345